By Professor David Simon Ziegler

Journal articles

Mateos MK; Ajuyah P; Fuentes-Bolanos N; El-Kamand S; Barahona P; Altekoester AK; Mayoh C; Holliday H; Liu J; Cui L; Pfaff E; Mackay A; Resnick AC; Pinese M; Lau LMS; Khuong-Quang DA; Dias K; Goudie C; Salkeld A; Rokita JL; Jones DTW; Juretic N; Hayden E; Pfister SM; Kramm CM; Blattner-Johnson M; Jabado N; Tsoli M; Vittorio O; Mueller S; Guo Y; Tucker K; Waszak SM; Perreault S; Jones C; Wong-Erasmus M; Cowley MJ; Ziegler DS, 2025, 'Germline analysis of an international cohort of pediatric diffuse midline glioma patients', Neuro Oncology, 27, pp. 1849 - 1863, http://dx.doi.org/10.1093/neuonc/noaf061

Upton DH; Liu J; George SM; Valvi S; Ung C; Rayner BS; Gopalakrishnan A; Pandher R; Khan A; Venkat P; Mayoh C; Holliday H; Yeung N; Nguyen H; Franshaw L; Ehteda A; Shen H; Farruggia G; Orienti I; Reynolds CP; Tsoli M; Ziegler DS, 2025, 'High-throughput in vitro drug screening and in vivo studies identify fenretinide as a brain-penetrant DMG therapeutic', Neuro Oncology, 27, pp. 1813 - 1828, http://dx.doi.org/10.1093/neuonc/noaf035

Karol SE; Khaw SL; Zwaan CM; Baruchel A; Bittencourt H; Cooper TM; Flotho C; Fraser C; Forlenza CJ; Goldsmith KC; Macy ME; Morgenstern DA; O'Brien MM; Petit A; Ziegler DS; Reinhardt D; Opferman JT; Rubnitz JE; Onishi M; Dunshee DR; Dunbar F; Vishwamitra D; Ross JA; Chen X; Unnebrink K; Kammerlander M; Salem AH; Palenski TL; Sunkersett G; Place AE, 2025, 'Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia', Pediatric Blood and Cancer, 72, http://dx.doi.org/10.1002/pbc.31714

Macy ME; Naranjo A; Zhang FF; Acord M; Cash T; DuBois SG; Foster JH; Knight KR; Hogarty MD; Mody R; Morgenstern DA; Parisi MT; Pinto N; Reynolds CP; Keyel ME; Shulkin BL; Ziegler DS; Bagatell R; Park JR; Goldsmith KC, 2025, 'A phase 2 randomized study of chemoimmunotherapy with or without eflornithine (DFMO) in relapsed/refractory neuroblastoma: A Children's Oncology Group (COG) report.', JOURNAL OF CLINICAL ONCOLOGY, 43, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.10001

Doz F; Casanova M; Koh K-N; Nysom K; Canete A; Kang HJ; Karajannis MA; Hargrave DR; Corradini N; Wu Y; Wang H; Ziegler DS; Prud'homme N; Manzitti C; Campbell-Hewson Q; Sturm C; Xu T; Sutaria DS; Mussai F; Gajjar AJ, 2025, 'Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: A data update from the iMATRIX alectinib phase I/II open-label, multi-center study.', JOURNAL OF CLINICAL ONCOLOGY, 43, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.10004

Witt O; Chi SN; Kang HJ; Ziegler DS; Baxter PA; Bailey S; Driever PH; Leary S; McCowage GB; Perreault S; Waanders AJ; Landi DB; Kilburn LB; Hansford J; Khuong-Quang D-A; Nysom K; Bailey-Torres A; Qiu J; McLeod L; van der Lugt J, 2025, 'Post hoc analysis of rashes reported in patients (pts) with BRAF-altered relapsed/refractory (r/r) pediatric low-grade glioma (pLGG) treated with the type II RAF inhibitor tovorafenib in FIREFLY-1.', JOURNAL OF CLINICAL ONCOLOGY, 43, pp. 10037 - 10037, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.10037

Mondal S; Liu PY; Seneviratne J; De Weck A; Venkat P; Mayoh C; Wu J; Maag J; Chen J; Wong M; Bartonicek N; Khoo P; Jin L; Ludlow LE; Ziegler DS; Trahair T; Mestdagh P; Cheung BB; Li J; Dinger ME; Street I; Zhang XD; Marshall GM; Liu T, 2025, 'The Super Enhancer-Driven Long Noncoding RNA PRKCQ-AS1 Promotes Neuroblastoma Tumorigenesis by Interacting With MSI2 Protein and Is Targetable by Small Molecule Compounds', Advanced Science, 12, pp. 2412520, http://dx.doi.org/10.1002/advs.202412520

Tsoli M; Chen Y; Gopalakrishnan A; Ung C; Khan A; Upton D; Ziegler DS, 2025, 'Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device', Journal of Visualized Experiments, 2025-May, http://dx.doi.org/10.3791/67349

Bastien G; Mcanulty C; Sharafi H; Mahroug A; Elkrief L; Ziegler D; Dubreucq S; Juteau LC; Jutras-Aswad D, 2025, 'Is Naltrexone Effective and Safe for Treating Amphetamine-Type Stimulant Use Disorder? A Systematic Review and Meta-analysis', Journal of Addiction Medicine, 19, pp. 322 - 330, http://dx.doi.org/10.1097/ADM.0000000000001422

Nysom K; Kilburn LB; Leary SES; Landi DB; de Vos-Kerkhof E; Perreault S; Witt O; Ziegler DS; Driever PH; Franson AT; Baxter PA; Whipple NS; Kline C; Segal D; Jabado N; Bailey S; McCowage G; Hansford JR; Khuong-Quang DA; Gottardo NG; Hassall T; Han JW; Oren MY; Chi SN; Qiu J; Costa DD; Raju SG; Manley P; Hargrave D, 2025, 'Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/ refractory optic pathway glioma in the FIREFLY-1 trial', Neuro Oncology, 27, pp. 1341 - 1355, http://dx.doi.org/10.1093/neuonc/noae274

Brown MP; Khan S; Logan J; Truong NT; Ziegler DS; Gargett T; LeBlanc A, 2025, 'Abstract 2111: In vivo expansion of autologous GD2-CAR-T cells in patients with aggressive primary tumors may be impaired by previous alkylator therapy', Cancer Research, 85, pp. 2111 - 2111, http://dx.doi.org/10.1158/1538-7445.am2025-2111

Gadde S; Ng SW; Chung N; Wang Q; Doughty L; Nero T; Tsoli M; Ziegler D; Chesler L; Parker M; Kumar N; Cheung B; Marshall G, 2025, 'Abstract 6863: Development of MYCN/MYC inhibitors', Cancer Research, 85, pp. 6863 - 6863, http://dx.doi.org/10.1158/1538-7445.am2025-6863

Yazdani PA; Lamoureux A-A; Fisher MJ; Lemelle L; Elke P; Pfister SM; Orbach D; Raskin S; Drilon A; Zapotocky M; Tabori U; Hansford JR; Erker C; Gottardo NG; Ziegler DS; Lindsay H; Hoffman LM; Lassaletta A; Jabado N; Coleman C; Mueller S; Robison NJ; Geoerger B; Moertel CL; Clarke M; Resnick AC; Alves M; Doz F; Laetsch TW; Perreault S, 2025, 'Clinical Features and Outcomes of Central Nervous System Tumors with NTRK Gene Fusions (S29.005)', Neurology, 104, http://dx.doi.org/10.1212/wnl.0000000000208692

Robertson EG; Hetherington K; Hunter JD; McGillycuddy M; Venkatesha V; Lau LMS; Khuong-Quang DA; Ziegler DS; Wakefield CE, 2025, 'Whatever It Takes: Parents' Perspectives of Patient-Derived Xenograft Mouse Models for Poor Prognosis Childhood Cancer', JCO Precision Oncology, 9, pp. e2400840, http://dx.doi.org/10.1200/PO-24-00840

Lamoureux AA; Fisher MJ; Lemelle L; Pfaff E; Amir-Yazdani P; Kramm C; De Wilde B; Kazanowska B; Hutter C; Pfister SM; Sturm D; Jones DTW; Orbach D; Pierron G; Raskin S; Drilon A; Diamond EL; Harada G; Zapotocky M; Zamecnik J; Krskova L; Ellezam B; Weil AG; Venne D; Barritault M; Leblond P; Coltin H; Hammad R; Tabori U; Hawkins C; Hansford JR; Meyran D; Erker C; McFadden K; Sato M; Gottardo NG; Dholaria H; Nørøxe DS; Goto H; Ziegler DS; Lin FY; Parsons DW; Lindsay H; Wong TT; Liu YL; Wu KS; Franson AT; Hwang E; Aguilar-Bonilla A; Cheng S; Cacciotti C; Massimino M; Schiavello E; Wood P; Hoffman LM; Cappellano A; Lassaletta A; Van Damme A; Llort A; Gerber NU; Ceruso MS; Bendel AE; Skrypek M; Hamideh D; Mushtaq N; Walter A; Jabado N; Alsahlawi A; Farmer JP; Coleman C; Mueller S; Mazewski C; Aguilera D; Robison NJ; O’Halloran K; Abbou S; Berlanga P; Geoerger B; Øra I; Moertel CL; Razis ED; Vernadou A; Ducray F; Bronnimann C; Seizeur R; Clarke M; Resnick AC; Alves M; Jones C; Doz F; Laetsch TW; Perreault S, 2025, 'Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions', Clinical Cancer Research, 31, pp. 561 - 572, http://dx.doi.org/10.1158/1078-0432.CCR-24-0581

Ziegler DS; Fangusaro JR; Tsoli M; Vittorio O; Shai-Hee T; Minard C; Liu X; Reid JM; Yahya NA; Foster JH; Fox E; Weigel B, 2025, 'A phase 1 trial of the FACT inhibitor CBL0137 in pediatric patients with relapsed or refractory solid and CNS tumors: A report from the Children’s Oncology Group study PEPN2111.', Journal of Clinical Oncology, 43, pp. 10051 - 10051, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.10051

Mascarenhas L; Albert CM; Orbach D; DuBois SG; Federman N; van Tilburg CM; Blattmann C; Casanova M; Ziegler DS; Dierselhuis MP; Toledano H; Burcoveanu D-I; De La Cuesta E; Mussi CE; Neu N; Drilon A; Laetsch TW; Xu R-H, 2025, 'LAROTRECTINIB (LARO) SAFETY AND EFFICACY IN PATIENTS (PTS) WITH TRK FUSION SARCOMAS AND PROLONGED RESPONSE', ESMO Rare Cancers, 4, pp. 100043, http://dx.doi.org/10.1016/j.esmorc.2025.100043

Hansford JR; Bouche G; Ramaswamy V; Jabado N; Fonseca A; Moloney S; Gottardo NG; Robinson GW; Gajjar A; Tinkle CL; Fisher PG; Foreman N; Ashley DM; Ziegler DS; Eisenstat DD; Massimino M; Witt O; Bartels U; Rutkowski S; Hargrave D; Fouladi M; Pfister SM; Bouffet E, 2024, 'Comments and Controversies in Oncology: The Tribulations of Trials Developing ONC201', Journal of Clinical Oncology, 42, pp. 4126 - 4129, http://dx.doi.org/10.1200/JCO.24.00709

Haeusler GM; Dashti SG; James F; Babl FE; Borland ML; Clark JE; Padhye B; Tapp H; Alvaro F; Raj TS; Walwyn T; Ziegler DS; Super L; Hall L; Yeoh DK; Butters C; McMullan B; Hanna DMT; De Abreu Lourenco R; Slavin MA; Phillips B; Thursky KA, 2024, 'Impact of time to antibiotics on clinical outcome in paediatric febrile neutropenia: a target trial emulation of 1685 episodes', Lancet Regional Health Western Pacific, 53, http://dx.doi.org/10.1016/j.lanwpc.2024.101226

van Tilburg CM; Kilburn LB; Perreault S; Schmidt R; Azizi AA; Cruz-Martínez O; Zápotocký M; Scheinemann K; Meeteren AYNSV; Sehested A; Opocher E; Driever PH; Avula S; Ziegler DS; Capper D; Koch A; Sahm F; Qiu J; Tsao LP; Blackman SC; Manley P; Milde T; Witt R; Jones DTW; Hargrave D; Witt O, 2024, 'LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration', BMC Cancer, 24, http://dx.doi.org/10.1186/s12885-024-11820-x

Staunton J; Ajuyah P; Harris A; Mayoh C; Wong M; Rumford M; Sullivan PJ; Ekert PG; Fuentes-Bolanos N; Cowley MJ; Lau LMS; Ziegler DS; Barahona P; Manoharan N, 2024, 'Novel paediatric case of a spinal high-grade astrocytoma with piloid features in a patient with Noonan Syndrome', Npj Precision Oncology, 8, http://dx.doi.org/10.1038/s41698-024-00734-3

Hansford J; Valvi S; de Boer J; McCowage G; Govender D; Kirby M; Ziegler D; Manoharan N; Hassall T; Wainwright B; Alvaro F; Wood PJ; Eisenstat D; Quang DAK; Jenkins M; Dun M; Laughton SJ; Endersby R; Dodgshun A; Gottardo N, 2024, '“If you build it, they will come”: the convergence of funding, research and collaboration in paediatric brain cancer clinical trials', Medical Journal of Australia, 221, pp. 520 - 523, http://dx.doi.org/10.5694/mja2.52506

Perreault S; Khuong-Quang D-A; Kilburn LB; Landi DB; Leary SES; Bailey S; Larouche V; Nysom K; Driever PH; Baxter PA; Witt O; Oren MY; Abdelbaki MS; Kline C; Whipple NS; Ziegler DS; van der Lugt J; Hassall TE; Gerber NU; Segal D; Hansford JR; McCowage G; Kang HJ; Han JW; Hargrave D; Franson AT; Toledano H; Jabado N; Gottardo NG; N S; Oren L; Tan EEK; Mueller S; Hoke ME; Kim Y; Walter A; Da Costa D; Manley P; Waanders AJ, 2024, 'CTNI-09. TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY (R/R) PEDIATRIC LOW-GRADE GLIOMA (PLGG): RESULTS FROM PATIENTS ON A DRUG HOLIDAY (DH) IN THE PHASE 2 FIREFLY-1 TRIAL', Neuro-Oncology, 26, pp. viii96 - viii97, http://dx.doi.org/10.1093/neuonc/noae165.0377

Peipert J; Baxter PA; Yu S; Oestreicher N; Zelt S; Driever PH; Bailey S; McCowage G; Ziegler DS; Witt O; Kang HJ; Hassall TE; Han JW; Franson AT; Oren MY; Toledano H; Larouche V; Abdelbaki MS; Jabado N; Gottardo NG; Gerber NU; Whipple NS; Segal D; N S; Oren L; Tan EEK; Mueller S; Kilburn LB; Nysom K; Khuong-Quang D-A; Landi DB; van der Lugt J; Leary SES; Perreault S; Waanders AJ; Hargrave D; Kline C; McKenna C; Manley P; Raju SG; Hansford JR, 2024, 'NCOG-05. HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN THE PHASE 2 FIREFLY-1 (PNOC026) TRIAL OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY (R/R) PEDIATRIC LOW-GRADE GLIOMA (PLGG)', Neuro-Oncology, 26, pp. viii224 - viii225, http://dx.doi.org/10.1093/neuonc/noae165.0887

Mazariego C; Daly R; McGill B; Kelada L; McKay S; Hetherington K; Ziegler DS; Wakefield CE; Taylor N, 2024, 'Barriers to access of precision guided therapies for children with high-risk cancer', Pediatric Blood and Cancer, 71, http://dx.doi.org/10.1002/pbc.31147

Elkrief L; Sharafi H; Bakouni H; McAnulty C; Bastien G; Dubreucq S; Garel N; Trépanier A; Ziegler D; Jutras-Aswad D, 2024, 'Efficacy and Safety of Modafinil for Treatment of Amphetamine-Type Stimulant Use Disorder: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials: Efficacité et innocuité du modafinil pour le traitement des troubles liés à l'usage de stimulants de type amphétamine : revue systématique et méta-analyse d'essais randomisés contrôlés par placebo', Canadian Journal of Psychiatry, 69, pp. 793 - 805, http://dx.doi.org/10.1177/07067437241262967

Kerras S; Hetherington K; Toofanian S; Manoharan N; Ziegler DS; Mateos MK, 2024, 'Second Opinion Seeking in Paediatric Oncology: Motivations and Predictors', Psycho Oncology, 33, http://dx.doi.org/10.1002/pon.70011

Revon-Rivière G; Hetherington K; Siddiqi A; Wong L; Mitchell LG; Connolly D; Morgenstern D; Ziegler DS; Cohen-Gogo S, 2024, 'Abstract B066: Bridging patient reported outcomes and CTCAE to improve supportive care and trial design: The PROptimise initiative', Cancer Research, 84, pp. B066 - B066, http://dx.doi.org/10.1158/1538-7445.pediatric24-b066

Jose J; Choi P; Tsoli M; Gopalakrishnan A; Lee C; Park TII; Ziegler D; Denny W, 2024, 'AB005. Development of tumour specific therapy for treatment of diffuse intrinsic pontine glioma (DIPG)', Chinese clinical oncology, 13, pp. AB005, http://dx.doi.org/10.21037/cco-24-ab005

Boutin CA; Durocher F; Beauchemin S; Ziegler D; Chakra CNA; Dufresne SF, 2024, 'Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review', Clinical Infectious Diseases, 79, pp. 151 - 160, http://dx.doi.org/10.1093/cid/ciae203

Lau LMS; Khuong-Quang DA; Mayoh C; Wong M; Barahona P; Ajuyah P; Senapati A; Nagabushan S; Sherstyuk A; Altekoester AK; Fuentes-Bolanos NA; Yeung V; Sullivan A; Omer N; Diamond Y; Jessop S; Battaglia L; Zhukova N; Cui L; Lin A; Gifford AJ; Fleuren EDG; Dalla-Pozza L; Moore AS; Khaw SL; Eisenstat DD; Gottardo NG; Wood PJ; Tapp H; Alvaro F; McCowage G; Nicholls W; Hansford JR; Manoharan N; Kotecha RS; Mateos MK; Lock RB; Tyrrell V; Haber M; Trahair TN; Cowley MJ; Ekert PG; Marshall GM; Ziegler DS; Wong-Erasmus M, 2024, 'Precision-guided treatment in high-risk pediatric cancers', Nature Medicine, 30, pp. 1913 - 1922, http://dx.doi.org/10.1038/s41591-024-03044-0

Wang YZM; Kaj-Carbaidwala B; Lane A; Agarwal S; Beier F; Bertuch A; Borovsky KA; Brennan SK; Calado RT; Catto LFB; Dufour C; Ebens CL; Fioredda F; Giri N; Gloude N; Goldman F; Hertel PM; Himes R; Keel SB; Koura DT; Kratz CP; Kulkarni S; Liou I; Nakano TA; Nastasio S; Niewisch MR; Penrice DD; Sasa GS; Savage SA; Simonetto DA; Ziegler DS; Miethke AG; Myers KC, 2024, 'Liver disease and transplantation in telomere biology disorders: An international multicenter cohort', Hepatology Communications, 8, pp. e0462, http://dx.doi.org/10.1097/HC9.0000000000000462

Kline C; Waanders AJ; Ziegler DS; Kilburn LB; Nysom K; van der Lugt J; Hassall TE; Gerber NU; Segal D; Larouche V; Khuong-Quang D-A; Hansford JR; Leary SES; Driever PH; Bailey S; Perreault S; McCowage G; Witt O; Baxter PA; Kang HJ; Han JW; Hargrave D; Franson AT; Oren MY; Toledano H; Abdelbaki MS; Jabado N; Gottardo NG; Whipple NS; N S; Oren L; Tan EEK; Mueller S; Wright KD; Blackman SC; Qiu J; Podesta D; Walter A; Da Costa D; Manley P; McLeod L; Landi DB, 2024, 'LGG-40. TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY PEDIATRIC LOW-GRADE GLIOMA (PLGG): REVERSIBLE DECREASES IN GROWTH VELOCITY IN THE PHASE 2 FIREFLY-1 TRIAL', Neuro-Oncology, 26, http://dx.doi.org/10.1093/neuonc/noae064.431

Valvi S; Manoharan N; Mateos MK; Hassall TEG; Ziegler DS; McCowage GB; Dun MD; Eisenstat DD; Gottardo NG; Hansford JR, 2024, 'Management of patients with diffuse intrinsic pontine glioma in Australia and New Zealand: Australian and New Zealand Children's Haematology/Oncology Group position statement', Medical Journal of Australia, 220, pp. 533 - 538, http://dx.doi.org/10.5694/mja2.52295

Kelada L; Robertson EG; McKay S; McGill BC; Daly R; Mazariego C; Taylor N; Tyedmers E; Armitage N; Evans HE; Wakefield CE; Ziegler DS, 2024, 'Communicating with families of young people with hard-to-treat cancers: Healthcare professionals’ perspectives on challenges, skills, and training', Palliative and Supportive Care, 22, pp. 539 - 545, http://dx.doi.org/10.1017/S1478951523001992

Morgenstern DA; Casanova M; van Tilburg CM; Ziegler DS; Campbell M; Watt TC; Pappo AS; Laetsch TW; Liu D; Liming K; Kang S; Wright J; Kang HJ, 2024, 'Safety and efficacy of selpercatinib in pediatric patients with RET-altered solid tumors: Updated results from LIBRETTO-121.', Journal of Clinical Oncology, 42, pp. 10022 - 10022, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.10022

Robertson EG; Hetherington K; Daly R; Donoghoe MW; Handelsman N; Ziegler DS; Wakefield CE, 2024, 'The feasibility and acceptability of collecting psychosocial outcome measures embedded within a precision medicine trial for childhood cancer', Cancer Medicine, 13, http://dx.doi.org/10.1002/cam4.7339

Kline C; Waanders AJ; Ziegler DS; Kilburn LB; Nysom K; van der Lugt J; Hassall TE; Gerber NU; Segal D; Larouche V; Mueller S; Walter A; Manley P; McLeod L; Landi DB, 2024, 'Type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma (pLGG): Reversible decreases in growth velocity in the phase 2 FIREFLY-1 trial.', Journal of Clinical Oncology, 42, pp. 10036 - 10036, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.10036

Evans L; Walker R; MacDiarmid J; Brahmbhatt H; Anazodo A; McCowage G; Gifford AJ; Kavallaris M; Trahair T; Ziegler DS, 2024, 'A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT in Children with Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor', Targeted Oncology, 19, pp. 333 - 342, http://dx.doi.org/10.1007/s11523-024-01051-2

Kilburn LB; Khuong-Quang DA; Hansford JR; Landi D; van der Lugt J; Leary SES; Driever PH; Bailey S; Perreault S; McCowage G; Waanders AJ; Ziegler DS; Witt O; Baxter PA; Kang HJ; Hassall TE; Han JW; Hargrave D; Franson AT; Yalon Oren M; Toledano H; Larouche V; Kline C; Abdelbaki MS; Jabado N; Gottardo NG; Gerber NU; Whipple NS; Segal D; Chi SN; Oren L; Tan EEK; Mueller S; Cornelio I; McLeod L; Zhao X; Walter A; Da Costa D; Manley P; Blackman SC; Packer RJ; Nysom K, 2024, 'Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial, (Nature Medicine, (2023), 10.1038/s41591-023-02668-y)', Nature Medicine, 30, pp. 1500, http://dx.doi.org/10.1038/s41591-024-02910-1

Ercan AB; Aronson M; Fernandez NR; Chang Y; Levine A; Liu ZA; Negm L; Edwards M; Bianchi V; Stengs L; Chung J; Al-Battashi A; Reschke A; Lion A; Ahmad A; Lassaletta A; Reddy AT; Al-Darraji AF; Shah AC; Van Damme A; Bendel A; Rashid A; Margol AS; Kelly BL; Pencheva B; Heald B; Lemieux-Anglin B; Crooks B; Koschmann C; Gilpin C; Porter CC; Gass D; Samuel D; Ziegler DS; Blumenthal DT; Kuo DJ; Hamideh D; Basel D; Khuong-Quang DA; Stearns D; Opocher E; Carceller F; Baris Feldman H; Toledano H; Winer I; Scheers I; Fedorakova I; Su JM; Vengoechea J; Sterba J; Knipstein J; Hansford JR; Gonzales-Santos JR; Bhatia K; Bielamowicz KJ; Minhas K; Nichols KE; Cole KA; Penney L; Hjort MA; Sabel M; Gil-da-Costa MJ; Murray MJ; Miller M; Blundell ML; Massimino M; Al-Hussaini M; Al-Jadiry MF; Comito MA; Osborn M; Link MP; Zapotocky M; Ghalibafian M; Shaheen N; Mushtaq N; Waespe N; Hijiya N; Fuentes-Bolanos N; Ahmad O; Chamdine O; Roy P; Pichurin PN; Nyman P; Pearlman R; Auer RC; Sukumaran RK; Kebudi R; Dvir R; Raphael R; Elhasid R; McGee RB; Chami R; Noss R; Tanaka R; Raskin S; Sen S; Lindhorst S; Perreault S; Caspi S; Riaz S, 2024, 'Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study', Lancet Oncology, 25, pp. 668 - 682, http://dx.doi.org/10.1016/S1470-2045(24)00026-3

Ziegler DS; Lehmann R; Eisenstat DD, 2024, 'A paradigm shift in how we treat pediatric low-grade glioma—Targeting the molecular drivers', Neuro Oncology, 26, pp. 593 - 595, http://dx.doi.org/10.1093/neuonc/noae008

Jessop SJ; Fuentos-Bolanos N; Mayoh C; Dolman MEM; Tax G; Wong-Erasmus M; Ajuyah P; Tyrell V; Marshall GM; Ziegler DS; Lau LMS, 2024, 'High throughput screening aids clinical decision-making in refractory acute myeloid leukaemia', Cancer Reports, 7, http://dx.doi.org/10.1002/cnr2.2061

Carrier FM; Girard M; Zuo RM; Ziegler D; Trottier H; Chassé M, 2024, 'Intraoperative Vasoactive Medications and Perioperative Outcomes in Liver Transplantation: A Systematic Review and Network Meta-analyses', Transplantation, 108, pp. 854 - 873, http://dx.doi.org/10.1097/TP.0000000000004744

Hogarty MD; Ziegler DS; Franson A; Chi YY; Tsao-Wei D; Liu K; Vemu R; Gerner EW; Bruckheimer E; Shamirian A; Hasenauer B; Balis FM; Groshen S; Norris MD; Haber M; Park JR; Matthay KK; Marachelian A, 2024, 'Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial', British Journal of Cancer, 130, pp. 788 - 797, http://dx.doi.org/10.1038/s41416-023-02525-2

Brown MP; Gargett T; Truong NT; Vittorio O; Ziegler DS, 2024, 'Abstract 3636: Myeloid cell rebound associated with GD2-CAR-T cell therapy in solid tumor patients', Cancer Research, 84, pp. 3636 - 3636, http://dx.doi.org/10.1158/1538-7445.am2024-3636

Duchatel RJ; Jackson ER; Parackal SG; Kiltschewskij D; Findlay IJ; Mannan A; Staudt DE; Thomas BC; Germon ZP; Laternser S; Kearney PS; Jamaluddin MFB; Douglas AM; Beitaki T; McEwen HP; Persson ML; Hocke EA; Jain V; Aksu M; Manning EE; Murray HC; Verrills NM; Sun CX; Daniel P; Vilain RE; Skerrett-Byrne DA; Nixon B; Hua S; de Bock CE; Colino-Sanguino Y; Valdes-Mora F; Tsoli M; Ziegler DS; Cairns MJ; Raabe EH; Vitanza NA; Hulleman E; Phoenix TN; Koschmann C; Alvaro F; Dayas CV; Tinkle CL; Wheeler H; Whittle JR; Eisenstat DD; Firestein R; Mueller S; Valvi S; Hansford JR; Ashley DM; Gregory SG; Kilburn LB; Nazarian J; Cain JE; Dun MD, 2024, 'PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma', Journal of Clinical Investigation, 134, pp. e170329, http://dx.doi.org/10.1172/JCI170329

Ross SE; Holliday H; Tsoli M; Ziegler DS; Dinger ME, 2024, 'Abstract B015: RNA N6-methyladenosine (m6A) as a therapeutic target in Diffuse Midline Glioma (DMG)', Cancer Research, 84, pp. b015 - b015, http://dx.doi.org/10.1158/1538-7445.brain23-b015

Khan A; Gopalakrishnan A; Liu J; Burns MR; Tsoli M; Ziegler DS, 2024, 'Abstract B047: Inhibition of the polyamine pathway: a novel therapeutic approach to treat aggressive pediatric medulloblastoma', Cancer Research, 84, pp. B047 - B047, http://dx.doi.org/10.1158/1538-7445.brain23-b047

Sacks E; Brizuela V; Javadi D; Kim Y; Elmi N; Finlayson K; Crossland N; Langlois EV; Ziegler D; Parmar SM; Bonet M, 2024, 'Immigrant women’s and families’ views and experiences of routine postnatal care: findings from a qualitative evidence synthesis', BMJ Global Health, 8, http://dx.doi.org/10.1136/bmjgh-2023-014075

Back to profile page